Skip to main content
. 2015 Feb 27;4:372. doi: 10.3389/fonc.2014.00372

Table 4A.

PRBM1 (BAF180).

Mutations Tumor
TCGA: percentage
Tumor
Cosmic: percentage
IHC
Reference
No. Nabr (%) Abr (%) Total (%) Nabr (%) Abr (%) Total (%) Range (%)
Acute myeloid leukemia 197 0.00 0.00 0.00

Adrenocortical carcinoma 80 1.25 0.00 1.25

Bladder urothelial carcinoma 237 4.22 0.84 5.06 Bladder 5.8 0.0 5.8

Brain lower grade glioma 289 1.38 1.04 2.42

Breast invasive carcinoma 981 0.71 0.20 0.92 Breast 0.4 0.4 0.8

Cervical cancer 39 5.13 0.00 5.13

Colon adenocarcinoma 269 0.00 0.00 0.00 Colon 1.0 0.3 1.3

Endometrial cancer 248 3.23 1.61 4.84 Endometrium 3.7 1.7 5.3

Esophageal cancer 282 1.40 0.00 1.40 Esophageal 0.0 2.3 2.3

Glioblastoma multiforme 291 0.69 0.00 0.69

Head/neck cancer 306 2.29 1.31 3.59

Kidney chromophobe 66 0.00 0.00 0.00

Kidney renal clear-cell carcinoma 417 5.52 21.10 26.62 Kidney 5.0 22.5 27.5 54–68 (119)

Kidney renal papillary cell carcinoma 112 0.89 2.68 3.57

Lung adenocarcinoma 544 1.65 0.55 2.21 Lung 2.2 0.5 2.6

Lung squamous cell carcinoma 178 3.93 0.00 3.93

Ovarian carcinoma (serous) 230 0.00 0.00 0.00 Ovarian (serous) 0.0 0.2 0.2

Clear cell 0.0 0.0 0.0

Endometrioid 0.0 0.0 0.0

Pancreatic adenocarcinoma 57 2.20 1.10 3.30 Pancreatic 0.3 0.7 1.0

Prostate adenocarcinoma 251 0.00 0.00 0.00 Prostate 0.0 0.0 0.0

Rectum adenocarcinoma 116 3.45 0.86 4.31

Skin cutaneous melanoma 345 3.19 2.61 5.80 Melanoma 0.6 0.0 0.6

Stomach adenocarcinoma 245 2.86 0.82 3.67 Stomach 3.1 0.0 3.1

Thyroid carcinoma 405 0.00 0.00 0.00

Uterine carcinosarcoma 114 0.88 0.00 0.88

Hepatocellular carcinoma 202 4.95 0.99 5.94 Liver 1.9 0.5 2.4

Unweighted average 1.99 1.43 3.42 1.60 1.93 3.53